Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2001

View Archived Issues

Antibody-based therapeutics sought under MorphoSys-Biogen collaboration

Focus on antibody-based cancer therapeutics planned at Immunomedics

Novel antibiotic technology licensed by SIGA

Review of Aventis Behring's Rx for inherited emphysema to be fast-tracked by FDA

Arena to acquire Bunsen Rush Laboratories and its Melanophore Technology

Anticholinergic bronchodilator proves safe and effective as COPD maintenance therapy

Case-control study identifies association between phenylpropanolamine and hemorrhagic stroke

Benzydamine-based activators of soluble guanylate cyclase identified for optimization

Now available: CD-ROM of highlights from the XXII Congress of the ESC

Replagal BLA deemed not approvable by FDA; further data requested

Anagrelide designated an orphan drug by European Commission

Clinical trials expected to begin for ILX-651 this quarter

Effective anti-HIV agents with high selectivity related to T-140

J&J companies will collaborate on development of Maxia compounds for type 2 diabetes

Rho kinase antagonism as a therapeutic alternative for erectile dysfunction

United Therapeutics and Orphan Australia form distribution alliance for UT-15

InterMune seeks approval for Actimmune in Canada; initiates separate phase II trial

Skyrin: a mechanistically novel, small-molecule glucagon antagonist

Use of (S)-oxybutynin for asthma claimed by Sepracor in recent patent

Seroquel may be useful for treating weight gain in psychotic patients

Diphenylethylene and styrene derivatives useful for diabetes

Japanese lab discovers analgesic agents derived from coumarin

New prodrugs synthesized by Sumitomo useful for neurodegenerative disorders

Recent patent covers MMP and TACE inhibitors from Fuji Yakuhin

Therapeutically useful metalloproteinase inhibitors designed at Darwin Discovery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...